MMR/MSI in gastric and GEJ adenocarcinoma

1 EU-approved indication in gastric and GEJ adenocarcinoma needs a MMR/MSI result: pembrolizumab (2nd line, advanced).

Line of therapy

Approved indications, Gastric and GEJ adenocarcinoma
DrugBiomarker requirementRegimenSettingConditions
dMMR / MSI-H1
Monotherapy
2L
advanced
Disease progression on or following at least one prior therapy

4 approvals for Gastric/GEJ need no biomarker and apply whatever the result. All approvals for Gastric/GEJ

See also

Label wording1

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Pembrolizumab (Keytruda)
    unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.